市場調査レポート
商品コード
1486814

がんバイオマーカーの世界市場:2033年までの機会と戦略

Cancer Biomarker Global Market Opportunities And Strategies To 2033

出版日: | 発行: The Business Research Company | ページ情報: 英文 302 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.54円
がんバイオマーカーの世界市場:2033年までの機会と戦略
出版日: 2024年05月30日
発行: The Business Research Company
ページ情報: 英文 302 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のがんバイオマーカー市場は2018年に104億7,392万米ドルと評価され、2023年まで13.50%以上のCAGRで成長しました。

個別化医療に対する需要の増加

個別化医療に対する需要の増加は、がんバイオマーカー市場の成長を促進しました。個別化医療は、精密医療または個別化医療とも呼ばれ、各患者の特性に合わせた治療や介入を目指す医療へのアプローチです。個別化医療は、遺伝子組成、バイオマーカープロファイル、その他の変数を含む、各患者の固有の属性に合わせて医療をカスタマイズしようとするものです。従来の画一的な方法と比較すると、治療のための特定の分子標的の特定にバイオマーカーを使用することで、より高い有効性と副作用の少ない標的医薬品を開発することができます。例えば、2022年10月、米国を拠点とし、科学者、患者、医療提供者を代表する組織である個別化医療連合(Personalized Medicine Coalition、患者とヘルスケアシステムに利益をもたらす個別化医療の理解と普及を推進)によると、複数のタイプのがん、遺伝性希少疾患、さまざまな慢性疾患や感染症の患者向けに、75,000を超える遺伝子検査製品と300を超える個別化医薬品が市場に出回っていると推定されています。さらに、個別化医療を提唱する米国の個別化医療連合(PMC)によると、2022年には米国食品医薬品局が承認する新薬の34%を個別化医薬品が占めるようになり、過去8年間はいずれも承認の25%以上を個別化医薬品が占めています。そのため、個別化医療に対する需要の増加が、歴史的な期間におけるがんバイオマーカー市場の成長を支えました。

目次

第1章 エグゼクティブサマリー

  • がんバイオマーカー- 市場の魅力とマクロ経済情勢

第2章 目次

第3章 表一覧

第4章 図一覧

第5章 レポート構成

第6章 市場の特徴

  • 一般的な市場の定義
  • 概要
  • がんバイオマーカー市場定義とセグメンテーション
  • バイオマーカータイプ別:市場セグメンテーション
    • タンパク質バイオマーカー
    • 遺伝子バイオマーカー
    • その他のがんバイオマーカー
  • プロファイリング技術別:市場セグメンテーション
    • オミックス技術
    • イメージング技術
    • 免疫学的検査
    • バイオインフォマティクス
    • 細胞遺伝学
  • がんタイプ別:市場セグメンテーション
    • 子宮頸がん
    • 乳がん
    • 肺がん
    • 大腸がん
    • 前立腺がん
    • 脳および中枢神経系のがん
    • 腎臓がん
    • 卵巣がん
    • 胃がん
    • その他のがんタイプ
  • 用途別:市場セグメンテーション
    • 診断
    • 研究開発
    • 予測
    • リスクアセスメント
    • その他の用途

第7章 主要な市場動向

  • がん診断とがん治療薬の進歩に向けたAIソリューションに注目
  • 市場での地位を強化するための戦略的パートナーシップとコラボレーション
  • がんの早期発見のためのバイオマーカー開発のための研究センターの設立
  • がん検出のための血液循環バイオマーカーの開発
  • がんバイオマーカーの放射性リガンド療法の開発に焦点を当てる

第8章 がんバイオマーカー市場:マクロ経済シナリオ

  • COVID-19の影響:がんバイオマーカー市場
  • ウクライナ戦争の影響:がんバイオマーカー市場
  • 高インフレの影響:がんバイオマーカー市場

第9章 世界の市場規模と成長

  • 市場規模
  • 市場成長実績, 2018-2023
    • 市場促進要因2018-2023
    • 市場抑制要因2018-2023
  • 市場成長予測, 2023-2028, 2033F
    • 市場促進要因2023-2028
    • 市場抑制要因2023-2028

第10章 世界のがんバイオマーカー市場:セグメンテーション

  • 世界のがんバイオマーカー市場:バイオマーカータイプ別、実績と予測, 2018-2023, 2028F, 2033F
  • 世界のがんバイオマーカー市場:プロファイリング技術別、実績と予測, 2018-2023, 2028F, 2033F
  • 世界のがんバイオマーカー市場:用途別、実績と予測, 2018-2023, 2028F, 2033F
  • 世界のがんバイオマーカー市場:がんタイプ別、実績と予測, 2018-2023, 2028F, 2033F

第11章 がんバイオマーカー市場:地域・国別分析

  • 世界のがんバイオマーカー市場:地域別、実績と予測, 2018-2023, 2028F, 2033F
  • 世界のがんバイオマーカー市場:国別、実績と予測, 2018-2023, 2028F, 2033F

第12章 アジア太平洋市場

第13章 西欧市場

第14章 東欧市場

第15章 北米市場

第16章 南米市場

第17章 中東市場

第18章 アフリカ市場

第19章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Roche Diagnostics
  • Novartis AG
  • Illumina Inc.
  • Hologic Inc
  • Thermo Fisher Scientific Inc.

第20章 競合ベンチマーキング

第21章 競合ダッシュボード

第22章 主要な合併と買収

  • Novartis Acquired MorphoSys
  • Bristol Myers Squibb Acquired Mirati Therapeutics
  • Agilent Acquired Avida Biomed
  • Quest Diagnostics Acquired Haystack Oncology
  • Prenetics Global Acquired ACT Genomics
  • Biocare Medical Acquired Empire Genomics
  • Agilent Acquired Resolution Bioscience
  • Hologic Acquired Biotheranostics

第23章 機会と戦略

  • 世界のがんバイオマーカー市場、2028年:新たな機会を提供する国
  • 世界のがんバイオマーカー市場、2028年:新たな機会を提供するセグメント
  • 世界のがんバイオマーカー市場、2028年:成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第24章 がんバイオマーカー市場:結論と提言

  • 結論
  • 提言
    • 製品
    • 場所
    • 価格
    • プロモーション
    • 人々

第25章 付録

目次
Product Code: o&s1203

Cancer biomarkers refer to biological molecules found in blood, other body fluids or tissues that are indicative of the presence of cancer in the body. These biomarkers can be proteins, genetic material or other types of molecules that provide critical information about the health status of an individual, especially in the context of cancer.

The cancer biomarker market consists of sales, by entities (organizations, sole traders and partnerships), of diagnostic products and services related to cancer biomarkers that are utilized by healthcare professionals and researchers for a variety of purposes, including the early detection of cancer, monitoring the progression of the disease, evaluating the effectiveness of treatment and predicting prognosis and the likelihood of cancer recurrence. They play a crucial role in personalized medicine, allowing for tailored treatment plans based on the specific biomarkers present in an individual's cancer.

The global cancer biomarker market was valued at $10,473.92 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 13.50%.

Increase In Demand For Personalized Medicine

An increase in demand for personalized medicine propelled the growth of the cancer biomarker market. Personalized medicine, also known as precision medicine or individualized medicine, is an approach to medical care that aims to tailor treatments and interventions to the specific characteristics of each patient. Personalized medicine seeks to customize medical care to each patient's unique attributes, including genetic composition, biomarker profile and other variables. When compared to conventional, one-size-fits-all methods, targeted medicines can be developed with greater efficacy and fewer adverse effects thanks to the use of biomarkers in the identification of specific molecular targets for therapy. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system) estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the increase in demand for personalized medicine supported the growth of the cancer biomarker market during the historic period.

Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs

Major companies are focused on an AI-driven solution for advancing cancer diagnostics utilizes machine learning algorithms to analyze medical imaging data such as X-rays, MRIs, CT scans and histopathology slides. These algorithms can detect subtle patterns and anomalies indicative of cancerous growths, enabling earlier and more accurate diagnoses. For instance, in September 2023, Ibex Medical Analytics, an Israel-based medical technology manufacturing company and leader in AI-powered cancer diagnostics, announced Galen Breast HER2, an artificial intelligence (AI) solution enhancing accurate and reproducible HER2 scoring in breast cancer patients. Galen Breast HER2 employs AI to detect invasive tumor areas and quantify HER2 expression into standard categories, aiding in patient identification for targeted therapies. The solution offers pathologists a comprehensive AI platform for analyzing H&E and IHC-stained slides, supporting quick and consistent HER2 scoring and enabling full review of breast biopsies with automated quantification of additional biomarkers.

The global cancer biomarker market is highly concentrated, with a few large players dominating in the market. The top ten competitors in the market made up to 51.6% of the total market in 2022

Cancer Biomarker Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global cancer biomarker market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for cancer biomarker? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The cancer biomarker market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider cancer biomarker market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by biomarkers type, by profiling technologies, by cancer type and by application.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the cancer biomarker market.
  • Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by biomarkers type, by profiling technologies, by cancer type and by application in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for cancer biomarker providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
  • 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay Bioinformatics; Cytogenetics
  • 3) By Application: Diagnostics; Research and Development; Prognostics; Risk Assessment; Other Applications
  • 4) By Cancer Type: Cervical Cancer; Breast Cancer; Lung Cancer; Brain and Central Nervous System Cancer; Kidney Cancer; Colorectal Cancer; Prostate Cancer; Ovarian Cancer; Stomach Cancer; Other Cancers
  • Companies Mentioned: Roche Diagnostics; Novartis AG; Illumina; Hologic Inc.; Thermo Fisher Scientific
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; cancer biomarker indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Cancer Biomarker - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Cancer Biomarker Market Definition And Segmentation
  • 6.4 Market Segmentation By Biomarkers Type
    • 6.4.1 Protein Biomarkers
    • 6.4.2 Genetic Biomarkers
    • 6.4.3 Other Cancer Biomarkers
  • 6.5 Market Segmentation By Profiling Technologies
    • 6.5.1 Omics Technologies
    • 6.5.2 Imaging Technologies
    • 6.5.3 Immunoassays
    • 6.5.4 Bioinformatics
    • 6.5.5 Cytogenetics
  • 6.6 Market Segmentation By Cancer Type
    • 6.6.1 Cervical Cancer
    • 6.6.2 Breast Cancer
    • 6.6.3 Lung Cancer
    • 6.6.4 Colorectal Cancer
    • 6.6.5 Prostate Cancer
    • 6.6.6 Brain And Central Nervous System Cancer
    • 6.6.7 Kidney Cancer
    • 6.6.8 Ovarian Cancer
    • 6.6.9 Stomach Cancer
    • 6.6.10 Other Cancer Types
  • 6.7 Market Segmentation By Application
    • 6.7.1 Diagnostics
    • 6.7.2 Research And Development
    • 6.7.3 Prognostics
    • 6.7.4 Risk Assessment
    • 6.7.5 Other Applications

7 Major Market Trends

  • 7.1 Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs
  • 7.2 Strategic Partnerships And Collaborations To Strengthen Market Position
  • 7.3 Establishment Of Centre Of Excellence To Develop Biomarkers For Early Detection Of Cancer
  • 7.4 Developments In Blood-Borne Circulating Biomarkers For Cancer Detection
  • 7.5 Focus On Development Of Radioligand Therapy For Cancer Biomarker

8 Cancer Biomarker Market - Macro Economic Scenario

  • 8.1 COVID-19 Impact On The Cancer Biomarker Market
  • 8.2 Impact Of The War In Ukraine On The Cancer Biomarker Market
  • 8.3 Impact Of High Inflation On The Cancer Biomarker Market

9 Global Market Size and Growth

  • 9.1 Market Size
  • 9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
    • 9.2.1 Market Drivers 2018 - 2023
    • 9.2.2 Market Restraints 2018 - 2023
  • 9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
    • 9.3.1 Market Drivers 2023 - 2028
    • 9.3.2 Market Restraints 2023 - 2028

10 Global Cancer Biomarker Market Segmentation

  • 10.1 Global Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 10.2 Global Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 10.3 Global Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 10.4 Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Cancer Biomarker Market, Regional and Country Analysis

  • 11.1 Global Cancer Biomarker Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 11.2 Global Cancer Biomarker Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

  • 12.1 Summary
  • 12.2 Market Overview
    • 12.2.1 Region Information
    • 12.2.2 Market Information
    • 12.2.3 Background Information
    • 12.2.4 Government Initiatives
    • 12.2.5 Regulations
    • 12.2.6 Regulatory Bodies
    • 12.2.7 Major Associations
    • 12.2.8 Taxes Levied
    • 12.2.9 Corporate Tax Structure
    • 12.2.10 Investments
    • 12.2.11 Major Companies
  • 12.3 Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.4 Asia-Pacific Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.5 Asia-Pacific Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.6 Asia-Pacific Cancer Biomarker Market: Country Analysis
  • 12.7 China Market
  • 12.8 Summary
  • 12.9 Market Overview
    • 12.9.1 Country Information
    • 12.9.2 Market Information
    • 12.9.3 Background Information
    • 12.9.4 Government Initiatives
    • 12.9.5 Regulations
    • 12.9.6 Regulatory Bodies
    • 12.9.7 Major Associations
    • 12.9.8 Taxes Levied
    • 12.9.9 Corporate Tax Structure
    • 12.9.10 Investments
    • 12.9.11 Major Companies
  • 12.10 China Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.11 China Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.12 China Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.13 India Market
  • 12.14 India Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.15 India Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.16 India Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.17 Japan Market
  • 12.18 Japan Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.19 Japan Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.20 Japan Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.21 Australia Market
  • 12.22 Australia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.23 Australia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.24 Australia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.25 Indonesia Market
  • 12.26 Indonesia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.27 Indonesia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.28 Indonesia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.29 South Korea Market
  • 12.30 South Korea Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.31 South Korea Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.32 South Korea Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

  • 13.1 Summary
  • 13.2 Market Overview
    • 13.2.1 Region Information
    • 13.2.2 Market Information
    • 13.2.3 Background Information
    • 13.2.4 Government Initiatives
    • 13.2.5 Regulations
    • 13.2.6 Regulatory Bodies
    • 13.2.7 Major Associations
    • 13.2.8 Taxes Levied
    • 13.2.9 Corporate Tax Structure
    • 13.2.10 Investments
    • 13.2.11 Major Companies
  • 13.3 Western Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.4 Western Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.5 Western Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.6 Western Europe Cancer Biomarker Market: Country Analysis
  • 13.7 UK Market
  • 13.8 UK Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.9 UK Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.10 UK Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.11 Germany Market
  • 13.12 Germany Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.13 Germany Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.14 Germany Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.15 France Market
  • 13.16 France Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.17 France Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.18 France Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.19 Italy Market
  • 13.20 Italy Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.21 Italy Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.22 Italy Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.23 Spain Market
  • 13.24 Spain Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.25 Spain Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.26 Spain Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

  • 14.1 Summary
  • 14.2 Market Overview
    • 14.2.1 Region Information
    • 14.2.2 Market Information
    • 14.2.3 Background Information
    • 14.2.4 Government Initiatives
    • 14.2.5 Regulations
    • 14.2.6 Regulatory Bodies
    • 14.2.7 Major Associations
    • 14.2.8 Taxes Levied
    • 14.2.9 Corporate Tax Structure
    • 14.2.10 Investments
    • 14.2.11 Major Companies
  • 14.3 Eastern Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.4 Eastern Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.5 Eastern Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.6 Eastern Europe Cancer Biomarker Market: Country Analysis
  • 14.7 Russia Market
  • 14.8 Russia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.9 Russia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.10 Russia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

  • 15.1 Summary
  • 15.2 Market Overview
    • 15.2.1 Region Information
    • 15.2.2 Market Information
    • 15.2.3 Background Information
    • 15.2.4 Government Initiatives
    • 15.2.5 Regulations
    • 15.2.6 Regulatory Bodies
    • 15.2.7 Major Associations
    • 15.2.8 Taxes Levied
    • 15.2.9 Corporate Tax Structure
    • 15.2.10 Investments
    • 15.2.11 Major Companies
  • 15.3 North America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.4 North America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.5 North America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.6 North America Cancer Biomarker Market: Country Analysis
  • 15.7 USA Market
  • 15.8 Summary
  • 15.9 Market Overview
    • 15.9.1 Country Information
    • 15.9.2 Market Information
    • 15.9.3 Background Information
    • 15.9.4 Government Initiatives
    • 15.9.5 Regulations
    • 15.9.6 Regulatory Bodies
    • 15.9.7 Major Associations
    • 15.9.8 Taxes Levied
    • 15.9.9 Corporate Tax Structure
    • 15.9.10 Investments
    • 15.9.11 Major Companies
  • 15.10 USA Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.11 USA Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.12 USA Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.13 Canada Market
  • 15.14 Canada Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.15 Canada Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.16 Canada Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

  • 16.1 Summary
  • 16.2 Market Overview
    • 16.2.1 Region Information
    • 16.2.2 Market Information
    • 16.2.3 Background Information
    • 16.2.4 Government Initiatives
    • 16.2.5 Regulations
    • 16.2.6 Regulatory Bodies
    • 16.2.7 Major Associations
    • 16.2.8 Taxes Levied
    • 16.2.9 Corporate Tax Structure
    • 16.2.10 Investments
    • 16.2.11 Major Companies
  • 16.3 South America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.4 South America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.5 South America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.6 South America Cancer Biomarker Market: Country Analysis
  • 16.7 Brazil Market
  • 16.8 Brazil Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.9 Brazil Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.10 Brazil Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

  • 17.1 Summary
  • 17.2 Market Overview
    • 17.2.1 Region Information
    • 17.2.2 Market Information
    • 17.2.3 Background Information
    • 17.2.4 Government Initiatives
    • 17.2.5 Regulations
    • 17.2.6 Regulatory Bodies
    • 17.2.7 Major Associations
    • 17.2.8 Taxes Levied
    • 17.2.9 Corporate Tax Structure
    • 17.2.10 Investments
    • 17.2.11 Major Companies
  • 17.3 Middle East Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 17.4 Middle East Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 17.5 Middle East Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

  • 18.1 Summary
  • 18.2 Market Overview
    • 18.2.1 Region Information
    • 18.2.2 Market Information
    • 18.2.3 Background Information
    • 18.2.4 Government Initiatives
    • 18.2.5 Regulations
    • 18.2.6 Regulatory Bodies
    • 18.2.7 Major Associations
    • 18.2.8 Taxes Levied
    • 18.2.9 Corporate Tax Structure
    • 18.2.10 Investments
    • 18.2.11 Major Companies
  • 18.3 Africa Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 18.4 Africa Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 18.5 Africa Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape and Company Profiles

  • 19.1 Company Profiles
  • 19.2 Roche Diagnostics
    • 19.2.1 Company Overview
    • 19.2.2 Products And Services
    • 19.2.3 Business Strategy
    • 19.2.4 Financial Overview
  • 19.3 Novartis AG
    • 19.3.1 Company Overview
    • 19.3.2 Products And Services
    • 19.3.3 Business Strategy
    • 19.3.4 Financial Performance
  • 19.4 Illumina Inc.
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
    • 19.4.3 Business Strategy
    • 19.4.4 Financial Overview
  • 19.5 Hologic Inc
    • 19.5.1 Company Overview
    • 19.5.2 Products And Services
    • 19.5.3 Business Strategy
    • 19.5.4 Financial Overview
  • 19.6 Thermo Fisher Scientific Inc.
    • 19.6.1 Company Overview
    • 19.6.2 Products And Services
    • 19.6.3 Business Strategy
    • 19.6.4 Financial performance

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

  • 22.1 Novartis Acquired MorphoSys
  • 22.2 Bristol Myers Squibb Acquired Mirati Therapeutics
  • 22.3 Agilent Acquired Avida Biomed
  • 22.4 Quest Diagnostics Acquired Haystack Oncology
  • 22.5 Prenetics Global Acquired ACT Genomics
  • 22.6 Biocare Medical Acquired Empire Genomics
  • 22.7 Agilent Acquired Resolution Bioscience
  • 22.8 Hologic Acquired Biotheranostics

23 Opportunities And Strategies

  • 23.1 Global Cancer Biomarker Market In 2028 - Countries Offering Most New Opportunities
  • 23.2 Global Cancer Biomarker Market In 2028 - Segments Offering Most New Opportunities
  • 23.3 Global Cancer Biomarker Market In 2028 - Growth Strategies
    • 23.3.1 Market Trend Based Strategies
    • 23.3.2 Competitor Strategies

24 Cancer Biomarker Market, Conclusions And Recommendations

  • 24.1 Conclusions
  • 24.2 Recommendations
    • 24.2.1 Product
    • 24.2.2 Place
    • 24.2.3 Price
    • 24.2.4 Promotion
    • 24.2.5 People

25 Appendix

  • 25.1 Geographies Covered
  • 25.2 Market Data Sources
  • 25.3 Research Methodology
  • 25.4 Currencies
  • 25.5 The Business Research Company
  • 25.6 Copyright and Disclaimer